Global Preclinical Imaging Market Size (2024 - 2029)

The preclinical imaging market is experiencing growth driven by advancements in molecular imaging technology and an increasing demand for non-invasive imaging techniques. The market's expansion is further supported by rising preclinical research funding from both private and public sectors. The COVID-19 pandemic has also influenced the market, as researchers have adapted to new challenges and increased the need for imaging tools to support antiviral research and vaccine testing. Technological innovations in multimodal molecular imaging are enhancing the ability to conduct real-time, non-invasive assessments at the cellular level, which is crucial for advancing personalized medicine and targeted therapies.

Home Market Analysis Healthcare Research Medical Devices Research Medical Imaging Research Diagnostic Imaging Research Preclinical Imaging Industry Market Size

Market Size of Global Preclinical Imaging Industry

Preclinical Imaging Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 6.00 %
Fastest Growing Market Europe
Largest Market North America

Major Players

Preclinical Imaging Market Major Players

*Disclaimer: Major Players sorted in no particular order

Preclinical Imaging Market Analysis

The preclinical imaging market is expected to register a CAGR of nearly 6.00% during the forecast period (2022-2027).

The current coronavirus disease 2019 (COVID-19) crisis has worsened, and clinical operations have changed dramatically. According to the article "The Current Coronavirus Disease 2019 (COVID-19) Crisis Continues to Grow and Has Resulted in Marked changes to clinical operations," published in 2020, academic medical centers and universities have rushed to shut down scientific research activities to maximize social distancing and minimize the spread of infection to research staff and others with whom they might come into contact, in parallel with clinical preparedness. Researchers in the field of radiology were wrestling with these issues, which will continue to affect present and future imaging studies.

However, with travel restrictions and improved sanitary precautions in place, Several manufacturers have resumed operations. Euro-BioImaging Nodes, for example, are tailored to the COVID-19 setting to give services to external users. Furthermore, Euro-BioImaging is assisting COVID-19-related research efforts, such as major drug screening projects, with picture data exchange. The company is collaborating with EU-OPENSCREEN, a partner research infrastructure. Using human cells and a SARS-CoV-2 isolate, EU-OPENSCREEN tested 5,632 chemicals for their ability to suppress viral-induced cytotoxicity to identify potential candidates for clinical trials against SARS-CoV-2. This is expected to boost the demand for preclinical imaging during the COVID-19 pandemic.

Also, in March 2020, MILabs improved their preclinical diagnostic U-CT system for in-vivo imaging of COVID-19 animal models in anticipation of rising demand for antiviral research tools and to enable the testing of coronavirus vaccines and medications. Ultra-high-resolution non-invasive lung imaging is one of the new features, allowing researchers to pinpoint the exact location of diseased processes in the bronchi of mice, guinea pigs, and ferrets. Furthermore, employing intrinsic freeze-frame lung imaging, up to four mice models can be scanned simultaneously for high-throughput screening of respiratory syndrome-associated coronavirus genotypes.

The major factors leading to the growth of the preclinical imaging market include the technological advancements in molecular imaging, increasing demand for non-invasive small animal imaging techniques, and an increase in preclinical research funding, by both private and public organizations.

Molecular imaging is a rapidly developing multidiscipline, which involves molecular biology, chemistry, computer, engineering, and medicine. It can recognize non-invasive and real-time visualization and measurement of the physiological or pathological process in the living organism at the cellular or molecular level.

Multimodal molecular imaging can play important role in the clinical care of various diseases by improving clinicians' ability to perform screening, surveillance, staging, prognosis, planning and therapy guidance, monitoring therapy efficacy, and assessing recurrence.

With its rapid technological advances, presymptomatic detection, targeted therapy, and personalized medicine may be possible shortly through the use of multimodal molecular imaging. Aspect imaging developed Aspect's M2 platform and the suite of products enable researchers to harness the power and quantitative insights of MRI for small animal phenotyping and drug development but without the cost, complexity, and technical burden of traditional MRI systems.

Preclinical Imaging Industry Segmentation

As per the scope of this report, preclinical imaging is the visualization technique employed on living animals for research purposes. The Preclinical Imaging Market is Segmented by Modality (Optical Imaging Systems, Nuclear Imaging Systems, Micro-MRI, Micro-ultrasound, Micro-CT, Photoacoustic Imaging Systems, and Others) and Geography (North America, Europe, Asia-Pacific, Middle-East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Modality
Optical Imaging Systems
Nuclear Imaging Systems
Micro-MRI
Micro-ultrasound
Micro-CT
Photoacoustic Imaging Systems
Other Modality
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Preclinical Imaging Market Size Summary

The preclinical imaging market is poised for significant growth, driven by technological advancements in molecular imaging and an increasing demand for non-invasive small animal imaging techniques. The market is experiencing a surge in interest due to its critical role in facilitating biomedical discovery and its applications in various fields such as cancer, cardiovascular disease, and developmental biology. The COVID-19 pandemic has further accelerated the demand for preclinical imaging, as researchers seek to develop antiviral research tools and test coronavirus vaccines and medications. The integration of multimodal molecular imaging is expected to enhance clinical care by improving screening, surveillance, and therapy guidance, thereby paving the way for presymptomatic detection and personalized medicine.

North America is anticipated to lead the preclinical imaging market, supported by a robust infrastructure, a high number of preclinical projects, and a strong adoption of advanced imaging devices. The United States, in particular, is witnessing accelerated growth due to increased research and development funding, the presence of major public and private companies, and a well-established research infrastructure. The market is moderately consolidated, with key players like Aspect Imaging Ltd, Bruker Corporation, and PerkinElmer Inc. actively engaging in new product launches and strategic acquisitions to maintain competitiveness. These factors, combined with the ongoing advancements in imaging technology, are expected to drive the market's expansion over the forecast period.

Explore More

Global Preclinical Imaging Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Technological Advancements in Molecular Imaging

      2. 1.2.2 Increasing Demand for Non-invasive Small Animal Imaging Techniques

      3. 1.2.3 Increase in Preclinical Research Funding, by Both Private and Public Organizations

    3. 1.3 Market Restraints

      1. 1.3.1 Strict Regulations in Preclinical Research

      2. 1.3.2 High Installation and Operational Costs associated with Preclinical Imaging Modalities

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Modality

      1. 2.1.1 Optical Imaging Systems

      2. 2.1.2 Nuclear Imaging Systems

      3. 2.1.3 Micro-MRI

      4. 2.1.4 Micro-ultrasound

      5. 2.1.5 Micro-CT

      6. 2.1.6 Photoacoustic Imaging Systems

      7. 2.1.7 Other Modality

    2. 2.2 Geography

      1. 2.2.1 North America

        1. 2.2.1.1 United States

        2. 2.2.1.2 Canada

        3. 2.2.1.3 Mexico

      2. 2.2.2 Europe

        1. 2.2.2.1 Germany

        2. 2.2.2.2 United Kingdom

        3. 2.2.2.3 France

        4. 2.2.2.4 Italy

        5. 2.2.2.5 Spain

        6. 2.2.2.6 Rest of Europe

      3. 2.2.3 Asia-Pacific

        1. 2.2.3.1 China

        2. 2.2.3.2 Japan

        3. 2.2.3.3 India

        4. 2.2.3.4 Australia

        5. 2.2.3.5 South Korea

        6. 2.2.3.6 Rest of Asia-Pacific

      4. 2.2.4 Middle-East and Africa

        1. 2.2.4.1 GCC

        2. 2.2.4.2 South Africa

        3. 2.2.4.3 Rest of Middle-East and Africa

      5. 2.2.5 South America

        1. 2.2.5.1 Brazil

        2. 2.2.5.2 Argentina

        3. 2.2.5.3 Rest of South America

Global Preclinical Imaging Market Size FAQs

The Global Preclinical Imaging Market is projected to register a CAGR of 6% during the forecast period (2024-2029)

Aspect Imaging Ltd, Bruker Corporation, Fujifilm Holdings Corporation, PerkinElmer Inc. and Milabs BV are the major companies operating in the Global Preclinical Imaging Market.

Preclinical Imaging Market Report Snapshots

Preclinical Imaging Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)